Novavax experiences COVID-19 vaccine was 90% efficient in Section 3 research

Novavax NVAX, +2.31% reported {that a} Section 3 research of its COVID-19 vaccine confirmed it was 90.4% efficient general. The 29,960-patient research additionally discovered that the vaccine supplied 100% safety towards reasonable and extreme illness. The corporate intends to file for regulatory authorizations within the third quarter, and it stated it stays on observe to


Novavax
NVAX,
+2.31%

reported {that a} Section 3 research of its COVID-19 vaccine confirmed it was 90.4% efficient general. The 29,960-patient research additionally discovered that the vaccine supplied 100% safety towards reasonable and extreme illness. The corporate intends to file for regulatory authorizations within the third quarter, and it stated it stays on observe to achieve manufacturing capability of 100 million doses per 30 days by the tip of the third quarter and 150 million doses per 30 days by the tip of the fourth quarter of 2021. Shares within the Gaithersburg, Md. firm jumped 8% in premarket commerce.



Supply hyperlink

The Fund Times
ADMINISTRATOR
PROFILE

Posts Carousel

Leave a Comment

Your email address will not be published. Required fields are marked with *

Latest Posts

Top Authors

Most Commented

Featured Videos